Dr. Reddy’s Laboratories stopped worldwide shipments of the heartburn drug ranitidine after the FDA found it contained N-nitrosodimethylamine, which is classified as a probable human carcinogen.
The Italian Drug Agency and Germany’s drug regulator will both order a recall of all versions of Zantac with an active ingredient made in India’s Saraca Laboratories, according to Bloomberg. Canada has also asked all makers of ranitidine-containing products to stop distribution.
Last week, Sandoz, the generic arm of Novartis, stopped worldwide distribution of its generic version of Zantac.
Sanofi, the maker of the brand-name Zantac medication, has not halted distribution of any ranitidine products outside of Canada.
Read the full report here.
More articles on pharmacy:
FDA approves first oral treatment for Type 2 diabetes
FDA finalizes rules to prevent improper petitions from delaying drug approvals
Pharmacists can play key role in preventing Hepatitis A outbreak
More articles on pharmacy:
FDA approves first oral treatment for Type 2 diabetes
FDA finalizes rules to prevent improper petitions from delaying drug approvals
Pharmacists can play key role in preventing Hepatitis A outbreak
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
